Search Results - Fabienne Dominjon
- Showing 1 - 2 results of 2
-
1
Effect of ivabradine in patients with heart failure with preserved ejection fraction: the <scp>EDIFY</scp> randomized placebo‐controlled trial by Michel Komajda, Richard Isnard, Alain Cohen‐Solal, Marco Metra, Burkert Pieske, Piotr Ponikowski, Adriaan A. Voors, Fabienne Dominjon, Cécile Henon‐Goburdhun, Matthieu Pannaux, Michael Böhm
Published 2017Artigo -
2
Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency by Stefan D. Anker, Stefan Schroeder, Dan Atar, Jeroen J. Bax, Claudio Ceconi, Martín Cowie, Adam Crisp, Fabienne Dominjon, Ian Ford, Hossein Ardeschir Ghofrani, Savion Gropper, Gerhard Hindricks, Mark A. Hlatky, Richard Holcomb, Narimon Honarpour, J. Wouter Jukema, Albert M. Kim, Michael Kunz, Martin Lefkowitz, Chantal Le Floch, Ulf Landmesser, Theresa A. McDonagh, John J.V. McMurray, Béla Merkely, Milton Packer, Krishna Prasad, James H. Revkin, Giuseppe Rosano, Ransi Somaratne, Wendy Gattis Stough, Adriaan A. Voors, Frank Ruschitzka
Published 2016Revisão
Search Tools:
Related Subjects
Heart failure
Internal medicine
Medicine
Randomized controlled trial
Adverse effect
Alternative medicine
Atrial fibrillation
Blood pressure
Cardiology
Clinical endpoint
Clinical trial
Ejection fraction
Heart rate
Intensive care medicine
Interquartile range
Ivabradine
Pathology
Physical therapy
Placebo
Sinus rhythm